Turning Precision Medicine into Action in Immuno-Oncology, Upcoming Webinar Hosted by Xtalks
In this free webinar, the featured speakers will discuss the benefits of ICH and flow cytometry in oncology drug development and how NGS testing for patient diagnostics is building databases for researchers. Attendees will learn how central and specialty laboratories can combine their efforts to meet the needs of immuno-oncology drug developers.
TORONTO, Sept. 15, 2021 /PRNewswire-PRWeb/ -- The challenges in immuno-oncology drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.
Immuno-oncology clinical trials have very low success rates, with just 5.3 percent of all drugs seeking an oncology indication eventually receiving approval. In the path to precision medicines, the use of molecular markers and protein biomarkers in both early- and late-stage immuno-oncology trials has become an increasingly important way to optimize patient selection, perform safety monitoring and measure drug efficacy at the tumor level. Immunohistochemistry (IHC), flow cytometry and next-generation sequencing (NGS) are complementary technologies that, together, offer comprehensive biological insights essential for immuno-oncology clinical trials.
Register for this webinar to learn why these technologies are essential to improve the odds of success in oncology drug development and how to find a central lab capable of developing customized assays with standardized SOPs across sites.
Join expert speakers from Cerba Research, Jérôme Sallette, Ph.D., Chief Scientific Officer, Cerba Healthcare; Sofie Vandevyver, Ph.D., Head of Business Operating and Marketing; Renaud Burrer, Ph.D., Head of Histopathology; and Nithianandan Selliah, Ph.D., Global Head of Flow Cytometry, as well as expert speakers from ACT Genomics, Shu Jen Chen, Ph.D., Chief Scientific Officer and George Wei, Ph.D., Vice President, R&D Division, in a live webinar with two broadcast dates on Monday, October 4, 2021 at 10am EDT (3pm BST/UK) and Tuesday, October 5, 2021 at 10am CST (China).
For more information, or to register for this event, visit Turning Precision Medicine into Action in Immuno-Oncology.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Sydney Perelmutter, Xtalks, +1 (416) 977-6555 x 352, [email protected]
SOURCE Xtalks
Share this article